Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADX-324 in Healthy Volunteers and Hereditary Angioedema
NCT05691361Phase 2Active, not recruiting
- Sponsor
- ADARx Pharmaceuticals
- Start
- Dec 2022
- Primary completion
- Dec 2027
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of onvuzosiran in hereditary angioedema (HAE) (3 arms), sponsored by ADARx Pharmaceuticals. Primary endpoint: Safety and Tolerability at 365 days. Started Dec 2022; status: active, not recruiting.
02
Drugs
onvuzosiran
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT05691361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05691361.